DOCSLIB.ORG

The MAS Omni QC Family

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The MAS Omni QC Family Thermo Scientific MAS Omni Quality Control Products Results you can trust The MAS Omni QC family Eliminate up to four routinely run vials Streamline your workflow Reduce your costs Streamline your workflow Consolidate multiple QC products Cardiac Panel QC STAT QC consolidated into: Omni•CARDIO Routine Immunoassay QC Tumor Marker QC Specialty Immunoassay QC General Chemistry QC consolidated into: Serum Protein / Immunology QC Omni•IMMUNE or consolidated into: Omni•IMMUNE PRO Omni•CORE MAS Omni•CARDIO™ Thermo Scientific™ MAS® Omni•CARDIO consolidates a comprehensive cardiac marker panel with the new generation of STAT analytes including D-Dimer, hCG, Myeloperoxidase and Procalcitonin. Value assignment is provided for key instrument systems including Abbott Architect, Beckman Coulter Access, AU and UniCel systems, Ortho Clinical Diagnostics VITROS, Roche Cobas and Elecsys systems and Siemens Advia, Dimension, Dimension Vista, Immulite and Stratus systems. Part Number Level Bottles & Size Storage & Stability Matrix OCRD-UL Ultra Low OCRD-L Low 36 months @ -25 to -15 ºC OCRD-101 1 15 days @ 2-8 ºC (for BNP-32, CK-MB, D-Dimer, OCRD-202 2 6 x 3 mL Assayed Digitoxin, hCG, hsCRP, Myeloperoxidase, Human Serum OCRD-303 3 Procalcitonin, Total CK, Troponin-I and Troponin-T) 10 days @ 2-8 ºC (for Myoglobin and NT-proBNP) Tri-Level Multi-Pack OCRD-MP (2 vials each level 1/2/3) Analytes Brain Natriuretic Peptide-32 (BNP-32) Beta Human Chorionic Gonadotropin (b-hCG) Procalcitonin (PCT) Creatinine Kinase-MB (CK-MB) High Sensitivity C-Reactive Protein (hsCRP) Total Creatinine Kinase (Total CK) D-Dimer Myeloperoxidase (MPO) Troponin I Digitoxin Myoglobin Troponin T Human Chorionic Gonadotropin (hCG) N-Terminal Brain Natriuretic Peptide (NT-proBNP) LabLink xL LabLink Extra Used in conjunction with MAS controls, Thermo Scientific Thermo Scientific LabLink Extra web-based QAP software LabLink xL web-based QAP software fulfills various works in unison with the LabLink xL Quality Assurance regulatory requirements for QC tracking, including peer Program to provide a gateway for up-to-the-minute support data review. data for the QC products manufactured by Thermo Fisher Scientific and the LabLink xL QAP system. • Get an external perspective on your internal day- to-day QC • Access to online QC package insert documents and updates • Troubleshoot variances immediately with visibility to a world-wide peer group of users • Quality Control handling and enhanced performance recommendations • Assess quickly and easily whether shifts in QC recoveries are unique to your laboratory • LabLink xL QC data file generation guidelines (LIS and Instrument Options) • Reduce troubleshooting time and quickly release patient results • Country specific technical support contact information available on demand MAS Omni•IMMUNE™ Thermo Scientific MAS Omni•IMMUNE & Omni•IMMUNE PRO Controls provide consolidation for routine immunoassay, tumor marker and specialty immunoassay QC processing into a single product, offering three distinct levels. Value assignment is provided for key integrated instrument systems including Abbott Architect, Beckman Coulter Access and UniCel, Ortho Clinical Diagnostics Vitros, Roche Cobas and Elecsys systems and Siemens Centaur, Dimension, Dimension Vista and Immulite. Part Number Level Bottles & Size Storage & Stability Matrix OIM-101 1 36 month shelf life @ -25 to -15 ºC 6 x 5 mL Assayed Human Serum OIM-202 2 30 days open vial @ 2 to 8 ºC OIM-303 3 MAS Omni•IMMUNE PRO™ Thermo Scientific MAS Omni•IMMUNE PRO Control provides Anti-Thyroglobulin (Anti-Tg), Anti-Thyroid Peroxidase (Anti-TPO) and Sex Hormone Binding Globulin (SHBG), in addition to the same analyte panel provided in the MAS Omni•IMMUNE product. Part Number Level Bottles & Size Storage & Stability Matrix OPRO-101 1 36 month shelf life @ -25 to -15 ºC 6 x 5 mL Assayed Human Serum OPRO-202 2 30 days open vial @ 2 to 8 ºC OPRO-303 3 Analytes New Specialty Tests Theophylline Follicle Stimulating Hormone (FSH) 25-OH-Vitamin D Tobramycin Human Chorionic Gonadotropin (hCG) Anti-Thyroglobulin (Anti-Tg) (PRO) Tricyclic Antidepressants (TCA) Beta Human Chorionic Gonadotropin (b-hCG) Anti-Thyroid Peroxidase (Anti-TPO) (PRO) Valproic Acid Lutenizing Hormone (LH) C-Peptide Vancomycin Progesterone Estriol, Free Prolactin Fructosamine Thyroid Function Tests Testosterone IGF-1 (insulin-like growth factor 1) Triiodothyronine, Free (FT3) Inhibin A Triiodothyronine, Total (TT3) Endocrine/Hormone Tests Phenytoin, Free Thyroxine, Free (FT4) Aldosterone Procalcitonin Thyroxine, Total (TT4) Cortisol Parathyroid Hormone (PTH) Thyroglobulin DHEA Sulfate Sex Hormone-Binding Globulin (SHBG) (PRO) Thyroid-Stimulating Hormone (TSH) Growth Hormone Thyroxine-Binding Globulin (TBG) Thyroid Uptake (T-Uptake) Valproic Acid, Free Cardiac Tests Tumor Marker Tests Homocysteine TDM/Toxicology Tests Adrenocorticotropic Hormone (ACTH) Acetaminophen Beta-2-microglobulin Anemia/Iron Deficiency Tests Amikacin CA 125 Ferritin Benzodiazepine CA 15-3 Folate (vitamin B9) Carbamazepine CA 19-9 Vitamin B12 Digoxin Carcinoembryonic Antigen (CEA) Disopyramide Gastrin Allergy Tests Ethosuximide Prostatic Acid Phosphatase (PAP) Immunoglobulin E (IgE) Gentamicin Prostate Specific Antigen, Free (FPSA) Lidocaine Prostate Specific Antigen, Total (TPSA) Lithium N-acetylprocainamide (NAPA) Reproductive/Fertility Tests Phenobarbital 17-OH-Progesterone Phenytoin Alpha-fetoprotein Primidone Estradiol Procainamide Quinidine Salicylate Refer to package insert for specific analyte and stability claims. Shelf life starts from the date of manufacture. Dropper Tips - Pkg 100 - MAS P/N 286-606 MAS Omni•CORE™ Thermo Scientific™ MAS® Omni•CORE Control consolidates general chemistry and serum protein QC processing into a single product, offering three distinct levels. Value assignment is provided for key integrated instrument systems, including Abbott Architect, Beckman Coulter AU, Synchron and UniCel, Ortho Clinical Diagnostics Vitros, Roche Cobas and Elecsys systems and Siemens Advia, Dimension and Dimension Vista. Part Number Level Bottles & Size Storage & Stability Matrix OCR-101 1 36 month shelf life @ -25 to -15 ºC OCR-202 2 6 x 5 mL Assayed 30 days open vial @ 2 to 8 ºC Human Serum OCR-303 3 (Bilirubin is 15 days open vial @ 2 to 8 ºC) Analytes General Chemistry LDL Cholesterol Methotrexate Endocrine/Hormone Tests Albumin Lipase N-acetylprocainamide (NAPA) Cortisol Alkaline Phosphatase (ALP) Magnesium Phenobarbital Alanine Aminotransferase (ALT) Osmolality Phenytoin Allergy Tests Amylase Phospholipids Primidone Immunoglobulin E (IgE) Amylase (pancreatic) Phosphorus Procainamide Aspartate Aminotransferase (AST) Potassium Quinidine Serum Proteins/Serology Tests Bile Acids Pseudocholinesterase (PCHE) Salicylate Alpha-1-Acid Glycoprotein Bilirubin, Conjugated Sodium Theophylline Alpha-1-Antitrypsin Bilirubin, Direct (DBIL) Total Protein Tobramycin Alpha-2-Macroglobulin Bilirubin, Neonatal Triglycerides Tricyclic Antidepressants (TCA) Antistreptolysin O (ASO) Bilirubin, Total (TBIL) Uric Acid Valproic Acid Apolipoprotein A1 Bilirubin, Unconjugated Zinc Vancomycin Apolipoprotein B Blood Urea Nitrogen (BUN) Beta-2-Microglobulin Calcium TDM/Toxicology Tests Anemia/Iron Deficiency Tests C3 Complement Chloride Acetaminophen Ferritin C4 Complement Cholesterol Amikacin Iron Ceruloplasmin Creatine Kinase (CK) Caffeine Iron Binding Capacity (IBC) C-Reactive Protein (CRP) Carbon Dioxide (CO2) Carbamazepine Iron Binding Capacity, Total (TIBC) Haptoglobin Copper Digoxin Iron Binding Capacity, Unsaturated (UIBC) Immunoglobulin A (IgA) Creatinine Disopyramide Transferrin Immunoglobulin G (IgG) Gamma-Glutamyl Ttransferase (GGT) Ethanol Immunoglobulin M (IgM) Glucose Ethosuximide Thyroid Function Tests Lipoprotein (a) HDL Cholesterol Gentamicin Thyroxine, Total (TT4) Prealbumin Lactic Acid Lidocaine Thyroid-Stimulating Hormone (TSH) Rheumatoid Factor Lactate Dehydrogenase (LDH) Lithium Thyroid Uptake (T-Uptake) ACCESS®, AU480®, AU680®, AU2700Plus®, AU5400®, Synchron®, UniCel®, Reg.TM: Beckman Coulter, Inc. Brea, CA Advia®, Reg.TM: Siemens Healthcare Diagnostics, Tarrytown, NY AIA® Reg.TM: Tosoh Biosciences, Inc., S. San Francisco, CA Architect®, Reg.TM: Abbott Laboratories, Inc., Abbott Park, IL Centaur®, Immulite®, Reg.TM: Siemens Healthcare Diagnostics, Tarrytown, NY Cobas®, Cobas Integra®, Elecsys®, Hitachi®, Reg.TM: Roche Diagnostics, Inc, Indianapolis, IN Dimension®, Dimension Vista®, EMIT®, Stratus®, Reg.TM: Siemens Healthcare Diagnostics, Glasgow, DE Liason® Reg.TM: Diasorin Inc, Stillwater, MN VITROS®, Reg.TM: Ortho-Clinical Diagnostics, Rochester, NY thermoscientific.com/diagnostics thermoscientific.com/qc © 2013 Thermo Fisher Scientific Inc. All rights reserved. Copyrights in and to portions of the illustrations are owned by a third party and licensed for limited use only to Thermo Fisher Scientific by Shutterstock. All other trademarks are the property of Thermo Fisher Scientific and its subsidiaries. Diagnostics USA Belgium, Netherlands & Luxembourg Germany Spain, Portugal & Italy 46360 Fremont Blvd. Tel. + 31 34 156 0744 Tel. + 49 851 88689 0 Tel. + 34 93589 8338 Fremont, CA 94538 USA [email protected] [email protected] [email protected] Tel. 800-232-3342 Canada New Zealand Switzerland & Austria [email protected] Tel. 905-286-4290 Tel. + 61 3 9757 4486 Tel. + 41 26 663 86 70 Asia Pacific [email protected] [email protected] [email protected] Fax + 61 2 9012 0023 China Nordic United Kingdom & Ireland [email protected] Tel. + 86 21 6865 4588 Tel. + 47 2 325 0433 Tel. + 44 1442 868 940 Australia [email protected] [email protected] [email protected] Tel. + 61 1800 333 110 France [email protected] Tel. + 33 4 7289 4400 [email protected] For countries not listed: [email protected] BN0628133 MASOMNI_2 9/2012.
Load more

Recommended publications
  • Ischemia-Modified Albumin Level in Type 2 Diabetes Mellitus
    Disease Markers 24 (2008) 311–317 311 IOS Press Ischemia-modified albumin level in type 2 diabetes mellitus – Preliminary report Agnieszka Piwowara,∗, Maria Knapik-Kordeckab and Maria Warwasa aDepartment of Pharmaceutical Biochemistry of Wroclaw Medical University, Wrocław, Poland bDepartment and Clinic of Angiology, Hypertension and Diabetology of Wroclaw Medical University, Wrocław, Poland Abstract. Aim: The main goal of the present study was the evaluation of ischemia-modified albumin (IMA) in patients with type 2 diabetes mellitus and estimation of its connection with vascular complications, glycemic control, hypertension, dyslipidemia and obesity. Methods: In 76 diabetic patients and 25 control subjects, a plasma level of IMA by manually performed, spectrophotometric Co(II)-albumin binding assay was determined. Other parameters such as glucose, fructosamine, HbA1c, total cholesterol and its fractions (HDL, LDL), triglicerydes were estimated by routine methods. Results: Diabetic patients had significantly higher level of IMA in comparison with control subjects. There were not significant differences between groups with various states of vascular complications although the lowest concentration of IMA was observed in patients with microangiopathy. Patients with poor glycemic control had higher IMA level in comparison with these with good glycemic control. Significant correlation was observed between IMA and HbA1c. Among the risk factors, only blood pressure and LDL showed a weak relationship with IMA level. Conclusions: Our results revealed, for the first time, higher level of IMA in diabetic patients which confirms that it may be of non-cardiac origin. We can suggest that the albumin molecule in plasma of diabetic patients is modified in the chronic hypoxia conditions provoked mainly by hyperglycemia and oxidative stress in diabetes.
    [Show full text]
  • The Evaluation of Cardiac Markers in Myocardial Infarction Patients
    Volume : 4 | Issue : 5 | May 2015 ISSN - 2250-1991 Research Paper Medical Science The Evaluation Of Cardiac Markers In Myocardial Infarction Patients Department of Medical Laboratory Science, College of Applied Ramprasad N Medical Sciences, Shaqra University, Al- Quwayiyah, Kingdom of Saudi Arabia, Corresponding Author Department of Medical Laboratory Science, College of Applied Samir Abdulkarim Medical Sciences, Shaqra University, Al- Quwayiyah, Kingdom of Alharbi Saudi Arabia Abdullah Habbab Laboratory Director, Diagnostic Laboratory, Al- Quwayiyah Gener- Alharbi al Hospital, Kingdom of Saudi Arabia. Background: Sudden cardiac death due to acute myocardial infarction (MI) is the most prevalent cause of death in young and adults. MI is a life threatening condition that needs emergency diagnosis and early treatment in the emergency room. Some researchers look for various clinical markers, which would help early diagnosis of the disease. Aim: In the present study, our aim was to investigate the lipid profile and cardiac enzymes in MI patients in Al- Quwayiyah region of Saudi Arabia. Materials and methods: This study included total 38 patients with MI and 46 age and sex matched healthy controls. Various lipid profile parameters and cardiac enzymes like Creatinine phosphokinase (CPK), Creatinine kinase- MB (CK- MB), lactate dehydrogenase (LDH), Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) levels were measured ABSTRACT and compared. This study was conducted in Al- Quwayiyah General Hospital, Saudi Arabia. Results: The significantly increased levels of cardiac enzymes (P<0.001) in MI patients when compared to control groups. Conclusion: The present study illustrated that assessing of lipid profiles and serum cardiac enzymes are the markedly very useful as it may serve as a useful monitor to judge the prognosis of the MI patients.
    [Show full text]
  • A Comparative Study of Creatine Kinase-MB and Troponin Levels Among Diabetic and Non Diabetic Patients with Acute MI
    ORIGINAL ARTICLE A comparative study of Creatine Kinase-MB and Troponin levels among diabetic and non diabetic patients with Acute MI AWAIS ANWAR1, HASAN AKBAR KHAN2, SAMRA HAFEEZ3, KANWAL FIRDOUS4 ABSTRACT In diabetic patients myocardial infarction (MI) is a major cause of death. Weak metabolic control is very common in diabetic patients with MI and if blood glucose levels are not controlled with different treatments may produce medical complications. Hyperglycemia, CK-MB and tropanin levels are very important biomarkers for the assessment of MI. The blood glucose (325.56±23.6), CK-MB (350.6±95.23) and Tropanin (6.16±2.23) levels in diabetics individuals showed P<0.001 significant results. Key words: Myocardial infarction (MI),Creatine kinase (CK),Tropanin. INTRODUCTION produced in pregnant ladies without any diabetic history due to the stress (Kosaka et al., 2005). Commonly myocardial infarction (MI) or acute Creatine kinase (CK) is an intracellular enzyme myocardial infarction (AMI) is called heart attack and found its high quantity in skeletal muscles, it occurs by the blockages of blood supply to a part of myocardium, and brain; smaller amounts also occur the heart (Agarwall,. 2009). When supply of blood in other visceral tissues. A CK-MB test is used as stops to the heart it causes damaging of the heart biological parameter in MI (Zeller et al., 2005). In the muscle. There are many symptom of MI but the most case of MI its concentration in the blood increases common is chest pain or which may travel into the than the normal levels. Different researchers found shoulder, arm, back, neck, or jaw that creatine kinase levels increases due to heart (Aghaeishahsavari,.
    [Show full text]
  • Lifesign MI 3-In-1 Package Insert.Pdf
    MIMyoglobin/CK-MB/Troponin I 3 IN 1 Point-of-care cardiac tests for the simultaneous qualitative detection of Myoglobin, CK-MB and Troponin I in blood, plasma and serum for the rapid diagnosis of myocardial infarction Manufactured by MF Manufactured for: EC REP Princeton BioMeditech Corp. MT Promedt Consulting GmbH 4242 U.S. Hwy 1 A PBM Group Company Altenhofstrasse 80 Monmouth Junction, NJ 08852 66386 St. Ingbert 85 Orchard Road Germany Skillman,NJ 08558 +49-68 94-58 10 20 800-526-2125, 732-246-3366 596 -4/24/12 www.lifesignmed.com P-56331-B LifeSign MI® Myoglobin/CK-MB/Troponin I Rapid Test For in vitro Diagnostic Use Only A Simple and Rapid One-Step Immunoassay for the Simultaneous Qualitative Detection of Myoglobin, CK-MB, and Cardiac Troponin I in Human Whole Blood, Serum, or Plasma. Intended Use: For the simultaneous qualitative determination of myoglobin, CK-MB, and troponin I in human whole blood, plasma or serum as an aid in the diagnosis of acute myocardial infarction in emergency room, critical care, point-of-care, and hospital settings. The LifeSign MI® Myoglobin/CK-MB/Troponin I Test provides a qualitative analytical test result. The qualitative nature of this assay does not provide infor- mation about change - either the rise or fall - in the concentration of myoglobin, CK-MB, and cardiac troponin I with single testing. A quantitative method should be used, if desired, to quantitate the concentration of myoglobin, CK-MB, and cardiac troponin I at any given time. Only with serial testing could a temporal change in the level of myoglobin, CK-MB, and cardiac troponin I be concluded.
    [Show full text]
  • 3 in 1 Troponin/Myoglobin/CK-MB
    Cortez DIAGNOSTICS, INC. 21250 Califa St. Suite 102 and 116, Woodland Hills, CA 91367 USA Tel: (818) 591-3030 Fax: (818) 591-8383 E-mail: [email protected] Web site: www.rapidtest.com See external label 2°C-30°C =25 or 50 tests Cat. #166779-1-37 One Step Troponin I/ CKMB/ Myoglobin RapiCard™ InstaTest Cat # 166779-1-37 One-step immuno-chromatographic assay for the detection of cTnI, CK-MB, and Myoglobin in human whole blood, serum and plasma For in vitro Diagnostic Use INTENDED USE The Cortez AMI 3 IN 1 Test is a rapid immunoassay for the determination of Cardiac Troponin I (cTnI), Creatine Kinase MB (CK-MB), and Myoglobin in human whole blood, serum and plasma specimens at cutoff concentrations of 0.5ng/ml, 5.0ng/ml, and 80ng/ml respectively, as an aid in the diagnosis of Acute Myocardial Infarction (AMI). Test results should be interpreted by the physician along with other test results and patient clinical symptoms. SUMMARY AND EXPLANATION When the myocardial infarction (MI) occurs in the hypoperfused region of the myocardium, oxygen can no longer be supplied to the cells in the region. Cell death is inevitable if oxygen is not restored within 10-15 min. Cell death results in the release of certain proteins from within cytoplasm into the blood stream. Some proteins are exclusive to and predominant in the cardiac muscle cells; they can function as cardiac makers and be detected in the blood specimens of AMI patients by specialized immunoassays.1-3 Unfortunately none of cardiac markers that have been discovered show early release, have 100% cardiac specificity, and a substantial life time in circulation.
    [Show full text]
  • Stanovení Izoenzymů Laktátdehydrogenázy Elektroforézou V Agarózovém Gelu
    Use of enzymes as diagnostic markers Evaluation of lactate dehydrogenase (LDH) isoenzymes by agarose gel electrophoresis Lactate dehydrogenase LDH • tetramer § M (gene LDHA, ch.11) § H (gene LDHB, ch.12) • LDH1 (HHHH) 31-49% – heart, liver, erythrocytes • LDH2 (HHHM) 38-58% – reticuloendothelial system • LDH3 (HHMM) 5.5-16.5% – lungs • LDH4 (HMMM) 0-0.7% – kidney • LDH5 (MMMM) 0-1.5% – skeletal muscle, liver Lactate dehydrogenase § LDH 1 and LDH 2 – converts lactate into pyruvate in tissues with aerobic metabolism § LDH 4 a LDH 5 – converts pyruvate into lactate in tissues with anaerobic glycolysis Electrophoretic separation of LDH isoenzymes • agarose gel, TBE buffer • staining solution – lithium lactate – NAD+ – stain nitroblue tetrazolium – phenazine methosulphate – carrier of electrons between NADH and the dye • 5 % acetic acid Isoenzymes detection • lactate + NAD+ ĺ pyruvate + NADH + H+ • NADH + H+ + NBT ĺ NAD+ + formazan Enzymes • proteins catalyzing chemical reactions (not consumed) • holoenzyme = apoenzyme + cofactor • many enzymes rely on cofactor - small molecules required for the catalytic activity of enzymes - coenzyme - small organic molecules - prosthetic group - tightly bound cofactor • enzymes decrease the required activation energy • thus, in the presence of enzymes, reactions proceed at a faster rate • many enzyme-catalyzed reactions are reversible Enzyme-catalyzed reaction Active site of the enzyme • active site = small portion of enzyme molecule which actually binds the substrate • active site is the result of precise folding of the polypeptide chain - AA that may have been far apart in the linear sequence can come together to cooperate in the enzyme reaction Enzyme specifity • each enzyme has a unique 3-D shape and recognizes and binds only the specific substrate of a reaction • often – reaction with only one substrate • sometimes – reaction with group of similar substrates • eg.
    [Show full text]
  • Rapid Cardiac Panel Test 1
    MATERIAL PROVIDED RAPID CARDIAC PANEL TEST 1. RapidCardiac Panel Test device MATERIALS REQUIRED BUT NOT SUPPLIED 1. Vacutainer tube, or other appropriate tube, without anticoagulant FOR THE QUALITATIVE ASSESSMENT OF CARDIAC TROPONIN I, 2. Timer or clock CK-MB AND MYOGLOBIN IN HUMAN SERUM 3. Micropipetter (200 -1000 µL range) and pipet tips STORAGE Store the test device at 2 to 30 oC. Do Not Freeze. PRECAUTIONS Catalog Number: BQ015-RTCD 1. For in vitro diagnostic use only. 2. Do not use product beyond the expiration date. 3. Handle all specimens as potentially infectious. For in vitro Diagnostic Use SPECIMEN COLLECTION AND PREPARATION 1. The serum specimen should be collected under standard laboratory conditions 2. Patient samples performed best when tested immediately after collection. If the sample cannot be INTENDED USE tested within 24 hours, freeze until the test can be performed. Allow sample to reach room temperature The RapidCardiac Panel test is an immunochromatography based one step in vitro test. It is designed for before proceeding. qualitative determination of cardiac troponin I (cTnI), CK-MB and Myoglobin in human serum specimens as an aid 3. Sodium azide can be added as a preservative up to 0.1% without effecting the test results. in the diagnosis of myocardial infarction. QUALITY CONTROL SUMMARY AND EXPLANATION 1. The control band is an internal reagent and procedural control. It will appear if the test has been performed Cardiac troponin I (cTnI) is a cardiac muscle protein with a molecular weight of 22.5 kilodaltons. Together with correctly and the reagents are reactive. troponin T (TnT) and troponin C (TnC), TnI forms a troponin complex in heart to play a fundamental role in the 2.
    [Show full text]
  • Correlation of Various Cardiac Markers in Diagnosed Case of Acute MI
    IP International Journal of Forensic Medicine and Toxicological Sciences 2020;5(3):84–89 Content available at: https://www.ipinnovative.com/open-access-journals IP International Journal of Forensic Medicine and Toxicological Sciences Journal homepage: www.ipinnovative.com Original Research Article Correlation of various cardiac markers in diagnosed case of acute MI Nagsen P Kamble1,*, Gajanan S Chavan2 1Dept. Forensic Medicine, Government Medical College and Hospital, Nagpur, Maharashtra 2Dept. of Forensic Medicine, Grant Government Medical College, Mumbai, Maharashtra, India ARTICLEINFO ABSTRACT Article history: Introduction: The ischemic injury to the heart and its extent of damage is directly associate with the length Received 04-08-2020 of ischemia. For the post mortem diagnosis of MI during an autopsy poses a challenge, particularly in cases Accepted 10-08-2020 of very minute myocardial infract. Biochemical markers provide a very useful tool for the assessment of Available online 31-10-2020 acute coronary syndrome. These are total creatinine kinase, the MB isoforms and myoglobin,as well as the troponin I(cTnI) and cardiac troponin T (cTnT). The aim of the present study was to study status of cardiac markers like CPK-MB, LDH, Trop-I in diagnosed case of acute MI. Keywords: Material and Methods: In this prospective study, 35 cases of sudden death that were studied at tertiary Myocardial infraction care government hospital attached to post-mortem centre during the period from April 2017 to July2018 Biochemical markers for the underlying pathology for the sudden death by the assessment of various biochemical markers. LDH Results: It was observed that out of 35 cases, CPK-MB levels were elevated in 29 cases.
    [Show full text]
  • Cardiomyocytes Derived from Human Cardiopoieticamniotic Fluids
    www.nature.com/scientificreports OPEN Cardiomyocytes Derived from Human CardiopoieticAmniotic Fluids Angela Di Baldassarre 1, Maria A D’Amico1, Pascal Izzicupo1, Giulia Gaggi1, Simone Guarnieri2, Maria A Mariggiò2, Ivana Antonucci3, Barbara Corneo4, Dario Sirabella4, 3 1 Received: 8 December 2017 Liborio Stuppia & Barbara Ghinassi Accepted: 1 August 2018 Human amniotic fuid (hAF) cells share characteristics of both embryonic and adult stem cells. They Published: xx xx xxxx proliferate rapidly and can diferentiate into cells of all embryonic germ layers but do not form teratomas. Embryoid-bodies obtained from hAF have cardiac diferentiation potential, but terminal diferentiation to cardiomyocytes (CMs) has not yet been described. Our purpose was to promote cardiac diferentiation in hAFcells. Cells were exposed to inducing factors for up to 15 days. Only the subset of hAF cells expressing the multipotency markers SSEA4, OCT4 and CD90 (CardiopoieticAF cells) responded to the diferentiation process by increasing the expression of the cardiac transcription factors Nkx2.5 and GATA4, sarcomeric proteins (cTnT, α-MHC, α-SA), Connexin43 and atrial and ventricular markers. Furthermore, diferentiated cells were positive for the calcium pumps CACNA1C and SERCA2a, with approximately 30% of CardiopoieticAF-derived CM-like cells responding to cafeine or adrenergic stimulation. Some spontaneous rare beating foci were also observed. In conclusion, we demonstrated that CardiopoieticAF cells might diferentiate toward the cardiac lineage giving rise to CM-like cells characterized by several cardiac-specifc molecular, structural, and functional properties. Cardiovascular (CV) diseases are the main cause of mortality in the industrialized world, with an estimated 17.7 million deaths by CV in 2015, representing 31% of all global deaths1.
    [Show full text]
  • Testing for a Panel of Cardiac Markers Horizon Scan Report 0033 January 2014
    Diagnostic Evidence Co-operative Oxford Cooperative Oxford HR Diagnostics Evidence Cooperative Oxford Point-of-Care (POC) Testing for a panel of Cardiac Markers Horizon Scan Report 0033 January 2014 Clinical Question: 1. In patients presenting to Primary Care and the Emergency Department with acute chest pain, what is the accuracy and utility of a POC panel of cardiac markers compared to standard practice in diagnosing myocardial infarction? 2. In patients presenting to Primary Care and the Emergency Department with acute chest pain, what is the prognostic value of a POC panel of cardiac markers compared to standard practice in predicting short-term (up to six-month) future cardiac events? Background, Current Practice and Advantages over Existing Technology: Myocardial infarction (MI), ‘a heart attack’, is caused by myocardial ischaemia(1). Upon myocardial ischaemia, components of cardiac muscle are released into the blood stream(1). The detection of these biomarkers - cardiac troponin (cTn), myoglobin and creatine kinase MB isoenzyme (CK-MB) - form the foundation of MI diagnosis(2, 3). Due to its high cardiac specificity(2), the National Institute for Health and Clinical Excellence (NICE) currently recommends testing of troponin I or T on initial presentation to hospital and again 10-12 hours after the onset of symptoms(4). One limitation of this current protocol is troponin levels do not increase to a detectable level until 6 hours after the onset of symptoms(1), although limits of detection of troponin are diminishing with newer assays(5) (see concluding comments below). Myoglobin, however, is detectable within 1-2 hours of symptom onset(6), and generally returns back to normal levels within 24 hours of symptom onset(6).
    [Show full text]
  • Blood Chemistry Profile and Cardiac Troponin T Concentration in Thai Stray Dogs Infected with Heartworms
    Kasetsart J. (Nat. Sci.) 33 : 251 - 257 (1999) Blood Chemistry Profile and Cardiac Troponin T Concentration in Thai Stray Dogs Infected with Heartworms Choosri Sribhen1, ML.Narudee Kasemsant1, Santi Kaewmokul1, and Kosit Sribhen2 ABSTRACT To investigate blood chemistry profile and to determine levels of myocardial marker proteins in canine dirofilariasis, measurements of biochemical parameters in liver and renal profile as well as the activity of the enzyme creatine kinase (CK) and cardiac troponin T (cTnT) concentration were performed on 72 Thai stray dogs with and without the presence of heartworms. The results showed that, with the exception of the low levels of gamma-glutamyl transferase (GGT) and uric acid, levels of other blood chemistry variables are comparable to those obtained from human subjects. The relatively high activity of CK observed was probably due to skeletal muscle injury occurred during restraint of animals. The majority of dogs, on the other hand, exhibited virtually non-detectable cTnT concentration comparable to those observed in apparently healthy persons. Furthermore, there was no statistically significant difference in cTnT levels between asymptomatic dogs with and without the presence of heartworms. These results may provide a basis for future clinical studies on assessing the extent of myocardial cell damage in symptomatic heartworm disease. Key words : blood chemistry parameters, myocardial markers , canine heartworm infection INTRODUCTION used for testing of liver and renal malfunctions including the enzymes aspartate aminotransferase The infection of dogs with heartworms (AST) and alanine aminotransferase (ALT) as well appears to be common throughout the world. In as blood urea nitrogen (BUN) and creatinine many parts of the United States, there was a high respectively.
    [Show full text]
  • Cardiac Markers”— Why All the Confusion?
    “CARDIAC MARKERS”— WHY ALL THE CONFUSION? Richard Heitsman, MICT, Cardiac Specialist, National Accounts Manager Radiometer America Disclosures . This speaker is employed by Radiometer America-all material contained herein has been carefully reviewed in an effort to ensure no vendor bias has been included in this presentation. Toughts expressed in this presentation do not necessarily represent those of Radiometer America or its affiliates. If you perceive any bias, please address concerns to the speaker or meeting organizer as this is purely unintentional. Objectives Upon completion of this session the participant will be able to: 1. Describe the challenges associated with cardiac patient testing to both the laboratory and clinical staff. 2. Discuss the role the lab must play as educator to the clinical staff. 3. Delineate the differences between analytical and clinical performance of cardiac marker testing. How Laboratorians Rated The Importance of Cardiac Testing Clinical Laboratory News January 2010: Volume 36, Number 1 Definitions-- “U.S. spends an estimated $8 billion to $13 billion per year in managing chest pain patients in the ED. “And approximately up to 80 percent of these patients don’t have ACS.” Dr. Luis LeSaliva CAP Today Feb. 2009 2 Types of Myocardial Infarction STEMI (EKG Diagnosed) NSTEMI (Biomarker Confirmed) 400k Cases Annually in the United States 1.4m Cases Annually in the United States EKG Diagnosed Biomarker Diagnosed 50% Sensitivity? Sensitivity and Specificity Variable Photos courtesy of Boehringer Ingleheim International GmbH, by Lennart Nilsson. CARDIAC MARKERS— HISTORICAL OVERVIEW The 3 Main Markers of Necrosis Sources: Clinical Chemistry (2007;53:547–551). Circulation, April 3, 2007 CKMB-Then… .
    [Show full text]